(HAE) Haemonetics - Overview
Stock: Plasma, Hemostasis, Guidewire, Closure, Autotransfusion
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 43.8% |
| Relative Tail Risk | -9.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -27.88 |
| Character TTM | |
|---|---|
| Beta | 0.613 |
| Beta Downside | 0.159 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.04% |
| CAGR/Max DD | -0.19 |
Description: HAE Haemonetics January 11, 2026
Haemonetics (NYSE:HAE) is a Boston-based medical-technology firm that sells a broad portfolio of blood-management and procedural-guidance solutions to hospitals worldwide, ranging from automated plasmapheresis systems (NexSys PCS/PCS2) and donor-management software (NexLynk DMS, Donor360) to hemostasis analyzers (TEG, HAS) and catheter-based vascular closure devices (VASCADE).
The company’s revenue is heavily tied to the growth of the plasma-collection market, which analysts estimate will expand at ~5% CAGR through 2028 driven by rising demand for plasma-derived therapeutics and tighter FDA regulations that favor automated, traceable collection processes. In FY2023 Haemonetics reported $1.18 billion in revenue, with a 9% year-over-year increase in the Plasma Collection segment and an operating margin of roughly 12%.
Key economic drivers include aging demographics that increase surgical volume (orthopedic, cardiac, trauma) and the shift toward value-based care, which pushes hospitals to adopt blood-conservation technologies such as Cell Saver Elite + and the VASCADE closure platform. Additionally, the company benefits from recurring software-as-a-service revenue streams tied to its Donor360 and TEG Manager platforms, which have shown double-digit subscription growth in the past two years.
Haemonetics distributes its products through a mix of direct sales teams, independent distributors, and clinical specialists, allowing it to maintain high-touch relationships in niche hospital settings while scaling its software offerings globally.
For a deeper quantitative view, see the ValueRay analyst dashboard.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 168.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 8.68 > 1.0 |
| NWC/Revenue: 26.46% < 20% (prev 50.10%; Δ -23.64% < -1%) |
| CFO/TA 0.12 > 3% & CFO 289.0m > Net Income 168.2m |
| Net Debt (928.3m) to EBITDA (375.1m): 2.47 < 3 |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.7m) vs 12m ago -6.98% < -2% |
| Gross Margin: 58.71% > 18% (prev 0.55%; Δ 5816 % > 0.5%) |
| Asset Turnover: 53.46% > 50% (prev 53.91%; Δ -0.44% > 0%) |
| Interest Coverage Ratio: 12.43 > 6 (EBITDA TTM 375.1m / Interest Expense TTM 21.0m) |
Altman Z'' 2.29
| A: 0.14 (Total Current Assets 899.7m - Total Current Liabilities 548.3m) / Total Assets 2.44b |
| B: 0.14 (Retained Earnings 336.3m / Total Assets 2.44b) |
| C: 0.11 (EBIT TTM 260.9m / Avg Total Assets 2.48b) |
| D: 0.19 (Book Value of Equity 296.3m / Total Liabilities 1.59b) |
| Altman-Z'' Score: 2.29 = BBB |
Beneish M -3.15
| DSRI: 0.99 (Receivables 207.1m/213.5m, Revenue 1.33b/1.36b) |
| GMI: 0.93 (GM 58.71% / 54.68%) |
| AQI: 1.02 (AQ_t 0.51 / AQ_t-1 0.50) |
| SGI: 0.98 (Revenue 1.33b / 1.36b) |
| TATA: -0.05 (NI 168.2m - CFO 289.0m) / TA 2.44b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of HAE shares?
Over the past week, the price has changed by -10.98%, over one month by -28.31%, over three months by -11.58% and over the past year by -5.79%.
Is HAE a buy, sell or hold?
- StrongBuy: 3
- Buy: 5
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HAE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 92 | 55% |
| Analysts Target Price | 92 | 55% |
| ValueRay Target Price | 58.8 | -0.9% |
HAE Fundamental Data Overview February 03, 2026
P/E Forward = 12.1065
P/S = 2.4186
P/B = 3.636
P/EG = 1.0086
Revenue TTM = 1.33b USD
EBIT TTM = 260.9m USD
EBITDA TTM = 375.1m USD
Long Term Debt = 920.4m USD (from longTermDebt, last quarter)
Short Term Debt = 304.3m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 928.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.14b USD (3.21b + Debt 1.22b - CCE 296.4m)
Interest Coverage Ratio = 12.43 (Ebit TTM 260.9m / Interest Expense TTM 21.0m)
EV/FCF = 16.17x (Enterprise Value 4.14b / FCF TTM 256.1m)
FCF Yield = 6.19% (FCF TTM 256.1m / Enterprise Value 4.14b)
FCF Margin = 19.29% (FCF TTM 256.1m / Revenue TTM 1.33b)
Net Margin = 12.67% (Net Income TTM 168.2m / Revenue TTM 1.33b)
Gross Margin = 58.71% ((Revenue TTM 1.33b - Cost of Revenue TTM 548.3m) / Revenue TTM)
Gross Margin QoQ = 59.50% (prev 59.70%)
Tobins Q-Ratio = 1.70 (Enterprise Value 4.14b / Total Assets 2.44b)
Interest Expense / Debt = 0.59% (Interest Expense 7.21m / Debt 1.22b)
Taxrate = 24.57% (12.6m / 51.3m)
NOPAT = 196.8m (EBIT 260.9m * (1 - 24.57%))
Current Ratio = 1.64 (Total Current Assets 899.7m / Total Current Liabilities 548.3m)
Debt / Equity = 1.44 (Debt 1.22b / totalStockholderEquity, last quarter 849.2m)
Debt / EBITDA = 2.47 (Net Debt 928.3m / EBITDA 375.1m)
Debt / FCF = 3.63 (Net Debt 928.3m / FCF TTM 256.1m)
Total Stockholder Equity = 864.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.77% (Net Income 168.2m / Total Assets 2.44b)
RoE = 19.45% (Net Income TTM 168.2m / Total Stockholder Equity 864.8m)
RoCE = 14.61% (EBIT 260.9m / Capital Employed (Equity 864.8m + L.T.Debt 920.4m))
RoIC = 9.42% (NOPAT 196.8m / Invested Capital 2.09b)
WACC = 6.04% (E(3.21b)/V(4.44b) * Re(8.17%) + D(1.22b)/V(4.44b) * Rd(0.59%) * (1-Tc(0.25)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.74%
[DCF Debug] Terminal Value 87.94% ; FCFF base≈171.9m ; Y1≈212.0m ; Y5≈361.0m
Fair Price DCF = 194.8 (EV 10.05b - Net Debt 928.3m = Equity 9.12b / Shares 46.8m; r=6.04% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 85.79 | EPS CAGR: 11.65% | SUE: 4.0 | # QB: 1
Revenue Correlation: 83.32 | Revenue CAGR: 6.36% | SUE: 1.98 | # QB: 2
EPS next Year (2027-03-31): EPS=5.44 | Chg30d=-0.036 | Revisions Net=-1 | Growth EPS=+10.6% | Growth Revenue=+5.8%